<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03567278</url>
  </required_header>
  <id_info>
    <org_study_id>2009-01</org_study_id>
    <secondary_id>DE/CA84/73-KL-30-09</secondary_id>
    <nct_id>NCT03567278</nct_id>
  </id_info>
  <brief_title>Feasibility Trial on ACURATE™ Transapical Implantation in Patients With Severe Symptomatic Aortic Stenosis (2009-01)</brief_title>
  <acronym>TA-FIM</acronym>
  <official_title>Feasibility Trial on ACURATE™ Transapical Implantation in Patients With Severe Symptomatic Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symetis SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility Trial on the ACURATE TA™ transapical implantation in patients presenting severe&#xD;
      symptomatic aortic stenosis to collect human feasibility data pertaining to the safety and&#xD;
      performance of the device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single arm, prospective, multicenter, open trial up to 5 year follow-up with the SYMETIS&#xD;
      ACURATE TA™ which is an aortic bioprosthesis for minimal invasive implantation via&#xD;
      transapical access to treat patients with severe symptomatic aortic stenosis where&#xD;
      conventional aortic valve replacement (AVR) via open heart surgery is considered to be&#xD;
      associated with high surgical risk for evaluating the feasibility and performance of the&#xD;
      implantation and the safety at 30-Day follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Medical Device Study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of Major Adverse Valve-Related Events (MAVRE) related to ACURATE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance endpoint</measure>
    <time_frame>Up to 24-hours post-procedure</time_frame>
    <description>Stable ACURATE placement at intended site as assessed by angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance endpoint</measure>
    <time_frame>Up to 24-hours post-procedure</time_frame>
    <description>Adequate ACURATE device function as assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days, 60 days, 3 months, 6 months and 12 months</time_frame>
    <description>Freedom from Death at follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAVRE at follow-up</measure>
    <time_frame>discharge or 7 days, 3 months, 6 months and 12 months</time_frame>
    <description>Rate of MAVRE at follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE or Major Adverse Cardiac and Cerebrovascular Event</measure>
    <time_frame>1 month, 3 months, 6 months and 12 months</time_frame>
    <description>Rate of MACCE at follow up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Aortic Stenosis Symptomatic</condition>
  <arm_group>
    <arm_group_label>ACURATE TA™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients implanted with ACURATE TA™ Bioprosthesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACURATE TA™</intervention_name>
    <description>ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.</description>
    <arm_group_label>ACURATE TA™</arm_group_label>
    <other_name>ACURATE TA™ Transapical Aortic Bioprosthesis and Delivery System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 75 years;&#xD;
&#xD;
          -  Additive EuroSCORE &gt; 9 and/or STS &gt; 9%;&#xD;
&#xD;
          -  Severe symptomatic AS assessed by echocardiography, documented by a derived mean&#xD;
             gradient &gt; 40mmHg,and a native Aortic Valve Area (AVA) &lt; 0.8 cm² or Aortic Valve Area&#xD;
             Index (AVAI) &lt; 0.6 cm²/m²;&#xD;
&#xD;
          -  NYHA Functional Class &gt; II;&#xD;
&#xD;
          -  Aortic annulus (AAn) diameters between and including 21 mm up to 27 mm (21mm ≤ AAn&#xD;
             ≤27mm) by transoesophageal echocardiography;&#xD;
&#xD;
          -  Sinotubular junction (STJ) higher than 1,1times the native aortic annulus diameter&#xD;
             (AAn) [STJ&gt;1.1xAAn] AND STJ&lt;45mm by transoesophageal echocardiography;&#xD;
&#xD;
          -  Patient understands the implications of participating in the study and provides signed&#xD;
             informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Congenital unicuspid or bicuspid aortic valve;&#xD;
&#xD;
          -  Severe eccentricity of calcification;&#xD;
&#xD;
          -  Severe mitral regurgitation (&gt; 2°);&#xD;
&#xD;
          -  Pre-existing prosthetic heart valve in any position and /or prosthetic ring;&#xD;
&#xD;
          -  Severe transapical access problem, non-reachable LV apex;&#xD;
&#xD;
          -  Previous surgery of the LV using a patch, such as the Dor procedure;&#xD;
&#xD;
          -  Presence of apical LV thrombus;&#xD;
&#xD;
          -  Echocardiographic evidence of intracardiac mass, thrombus, or vegetation;&#xD;
&#xD;
          -  Acute Myocardial Infarction (AMI) within 1 month prior to the procedure;&#xD;
&#xD;
          -  PCI within 1 month prior to the procedure;&#xD;
&#xD;
          -  Previous Transient Ischemic Accident (TIA) or stroke in the last 3 months;&#xD;
&#xD;
          -  Untreated clinically significant CAD requiring revascularization;&#xD;
&#xD;
          -  Hemodynamic instability: systolic pressure &lt;90mmHg without afterload reduction, shock,&#xD;
             need for inotropic support or intra-aortic balloon pump;&#xD;
&#xD;
          -  Severe left ventricular dysfunction with a LV Ejection Fraction (LVEF) &lt; 25% by&#xD;
             echocardiography;&#xD;
&#xD;
          -  Calcified pericardium;&#xD;
&#xD;
          -  Septal hypertrophy;&#xD;
&#xD;
          -  Primary Hypertrophic Obstructive Cardiomyopathy (HOCM);&#xD;
&#xD;
          -  Active infection, endocarditis or pyrexia;&#xD;
&#xD;
          -  Active peptic ulcer or Gastrointestinal (GI) bleeding within the past 3 months;&#xD;
&#xD;
          -  Significant hepatic involvement (Child &gt; B);&#xD;
&#xD;
          -  Major lung disease (FEV &lt; 0.8 or FEV1% &lt; 30% of normal);&#xD;
&#xD;
          -  Pulmonary hypertension;&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy;&#xD;
&#xD;
          -  Hematologic disorder (WBC&lt;3000mm3, Hb&lt;9g/dL, platelet count &lt;50000 cells/ mm3);&#xD;
&#xD;
          -  Serum creatinine level greater than 3.0 mg/dL or chronic renal failure requiring&#xD;
             dialysis;&#xD;
&#xD;
          -  Neurological disease severely affecting ambulation or daily functioning, including&#xD;
             dementia;&#xD;
&#xD;
          -  Other procedure scheduled at the same time, whether surgery or percutaneous approach;&#xD;
&#xD;
          -  Emergency procedure;&#xD;
&#xD;
          -  Life expectancy &lt; 12 months due to non-cardiac co-morbid conditions;&#xD;
&#xD;
          -  Known hypersensitivity/contraindication to any study medication, contrast media, or&#xD;
             nitinol;&#xD;
&#xD;
          -  Currently participating in an investigational drug or another device study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedrich Mohr, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Leipzig GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kerckhoff Klinik GmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen Westdeutsches Herzzentrum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg Herz- und Gefäßchirurgie</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Klinik für Herz-und Gefäßchirurgie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>June 15, 2018</last_update_submitted>
  <last_update_submitted_qc>June 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe Symptomatic Aortic Valve Stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

